Staging of non-small cell lung cancer (NSCLC): a review
- PMID: 20833010
- DOI: 10.1016/j.rmed.2010.08.005
Staging of non-small cell lung cancer (NSCLC): a review
Abstract
Lung cancer remains the most common cause of cancer-related mortality in Scotland, accounting for 28.9% of all cancer deaths in 2007. (1) Current guidelines recommend assessment of patient fitness and operability by a multi-disciplinary team when selecting management options. (2-6) Two of the most important prognostic markers are the stage of disease and ECOG performance status. The most commonly used cancer staging system is the tumour, node, metastasis (TNM) staging system, which is maintained by the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC). In 1998, the International Association for the Study of Lung Cancer (IASLC) established The Lung Cancer Staging Project, collecting data on over 100,000 patients diagnosed with lung cancer between 1990-2000 worldwide, in order to revise the 6th edition TNM staging system for non-small cell lung cancer (NSCLC).(7) The 7th edition was published in late 2009. This review of staging in NSCLC, includes a summary of the different staging techniques currently available and the 7th edition TNM staging system for NSCLC.(8).
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Imaging and lung cancer.Minerva Chir. 2011 Jun;66(3):215-22. Minerva Chir. 2011. PMID: 21666558 Review.
-
Use of the proposals of the international association for the study of lung cancer in the forthcoming edition of lung cancer staging system to predict long-term prognosis of operated patients.Cancer J. 2010 Mar-Apr;16(2):176-81. doi: 10.1097/PPO.0b013e3181ce474e. Cancer J. 2010. PMID: 20404615
-
Non-small cell lung cancer staging: proposed revisions to the TNM system.Cancer Imaging. 2008 Sep 30;8(1):181-5. doi: 10.1102/1470-7330.2008.0029. Cancer Imaging. 2008. PMID: 18824424 Free PMC article. Review.
-
New TNM classification for non-small-cell lung cancer.Expert Rev Anticancer Ther. 2009 Apr;9(4):413-23. doi: 10.1586/era.09.11. Expert Rev Anticancer Ther. 2009. PMID: 19374596 Review.
-
CT, positron emission tomography, and MRI in staging lung cancer.Clin Chest Med. 2008 Mar;29(1):39-57, v. doi: 10.1016/j.ccm.2007.11.004. Clin Chest Med. 2008. PMID: 18267183 Review.
Cited by
-
PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies.Cancers (Basel). 2022 May 29;14(11):2689. doi: 10.3390/cancers14112689. Cancers (Basel). 2022. PMID: 35681669 Free PMC article. Review.
-
circGFRA1 Enhances NSCLC Progression by Sponging miR-188-3p.Onco Targets Ther. 2020 Jan 20;13:549-558. doi: 10.2147/OTT.S230795. eCollection 2020. Onco Targets Ther. 2020. PMID: 32021297 Free PMC article.
-
Prognostic stratification of patients with T3N1M0 non-small cell lung cancer: which phase should it be?Med Oncol. 2012 Jun;29(2):607-13. doi: 10.1007/s12032-011-9907-y. Epub 2011 Mar 24. Med Oncol. 2012. PMID: 21431959
-
Tumor infiltrating T cells influence prognosis in stage I-III non-small cell lung cancer.J Thorac Dis. 2020 May;12(5):1824-1842. doi: 10.21037/jtd-19-3414a. J Thorac Dis. 2020. PMID: 32642087 Free PMC article.
-
Immune Effect of T Lymphocytes Infiltrated by Tumors on Non-Small-Cell Lung Cancer.J Oncol. 2022 Sep 10;2022:4662874. doi: 10.1155/2022/4662874. eCollection 2022. J Oncol. 2022. PMID: 36124030 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
